chloroquine and derivatives for COVID-19 - live meta-analysis of clinical studies

Table Graph

chloroquine and derivatives - versus control - for COVID-19 pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
deaths	1.09 [0.99, 1.21]	< 1	0%	25 studies (25/-)	4.6 %	high	low	low	crucial	-
deaths (time to event analysis only)	1.10 [0.99, 1.23]	< 1	0%	2 studies (2/-)	3.9 %	some concern	not evaluable	moderate	crucial	-
clinical deterioration	1.00 [0.46, 2.17]	< 1	41%	3 studies (3/-)	50.5 %	high	not evaluable	low	important	-
clinical improvement	1.21 [0.88, 1.67]	> 1	37%	4 studies (4/-)	87.6 %	high	not evaluable	low	important	-
clinical improvement (14-day)	1.17 [0.62, 2.23]	> 1	20%	2 studies (2/-)	68.6 %	some concern	not evaluable	moderate	important	-
clinical improvement (time to event analysis only)	1.01 [0.59, 1.74]	> 1	0%	1 study (1/-)	51.7 %	high	not evaluable	low	important	-
death or ventilation	1.14 [1.03, 1.25]	< 1	0%	3 studies (3/-)	0.5 %	some concern	not evaluable	moderate	important	-
hospitalization	0.79 [0.42, 1.48]	< 1	0%	2 studies (2/-)	77.0 %	some concern	not evaluable	moderate	important	-
PCR-negative conversion	0.88 [0.63, 1.22]	> 1	0%	3 studies (3/-)	22.1 %	high	not evaluable	low	important	-
PCR-negative conversion (14-day)	0.91 [0.56, 1.48]	> 1	0%	2 studies (2/-)	35.7 %	some concern	not evaluable	moderate	important	-
PCR-negative conversion (7-day)	1.05 [0.53, 2.09]	> 1	0%	1 study (1/-)	55.2 %	NA	not evaluable		important	-
PCR-negative conversion (time to event analysis only)	0.85 [0.58, 1.23]	> 1	0%	1 study (1/-)	19.3 %	high	not evaluable	low	important	-
radiologic improvement (7-day)	3.43 [1.10, 10.70]	> 1	0%	1 study (1/-)	98.3 %	high	not evaluable	low	important	-
ICU admission	0.83 [0.35, 1.95]	< 1	0%	1 study (1/-)	66.8 %	some concern	not evaluable	moderate	non important	-
safety endpoints 00
cardiac arrest	1.92 [0.35, 10.49]	< 1	0%	1 study (1/-)	22.7 %	some concern	not evaluable	moderate	important	-
adverse events	2.40 [1.12, 5.13]	< 1	89%	10 studies (10/-)	1.2 %	high	low	low	non important	-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

chloroquine and derivatives - versus control - for COVID-19 pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00